Cyclosporin C2hour monitoring after renal transplantation

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 10, 2003, Pages 477-481

  Einecke, Gunilla ^a   Mai, I ^a   Fritsche, L ^a   Slowinski, T ^a   Waiser, J ^a   Glander, P ^a   Bohler T ^a   Neumayer, H H ^a   Budde, K ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Cyclosporin A; Renal transplant; Therapeutic drug monitoring

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; CYCLOSPORIN;

ACCURACY; ACUTE GRAFT REJECTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG SAFETY; EXPERIENCE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PATIENT SELECTION; POSTOPERATIVE PERIOD; PREDICTION; PROSPECTIVE STUDY; RECIPIENT; RELIABILITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; STANDARD; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TREATMENT OUTCOME; ABSORPTION; ADULT; AREA UNDER THE CURVE; BLOOD; GRAFT REJECTION; METHODOLOGY; TIME; TISSUE DISTRIBUTION;

ABSORPTION; ADULT; AREA UNDER CURVE; CYCLOSPORINE; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0141996223     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41477     Document Type: Article

References (23)

1. Barama A et al 2000 Lower cyclosporine exposure increases the risk for subclinical rejection in renal transplant recipients. Transplantation 69 (Suppl): S225, Abstract 431
2. Bennett WM 1996 Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther 34: 515-519
3. Cantarovich M, Besner JG, Barkun JS et al 1998 Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 12: 243-249
4. 2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients. Transplant Proc 33: 3133-3136
5. 2 monitoring in stable renal transplant recipients may reduce cyclosporine nephrotoxicity. American Transplant Congress, April 26 - May 1, 2002, Washington, Abstract 636
6. 2 concentrations in stable renal allograft recipients. Transplant Proc 33: 3102-3103
7. 2 blood levels in stable renal allograft recipients. Transplant Proc 34: 1738-1739
8. Gaspari E, Perico N, Signorini O et al 1998 Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Technical note. Kidney Int 54: 2146-2150
9. Halloran PF, Helms LM, Kung L et al 1999 The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 68: 1356-1361
10. Kahan BD, Welsh M, Schoenberg L et al 1996 Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic allograft rejection. Transplantation 62: 599-606
11. Kahan BD, Welsh M, Urbauer DL et al 2000 Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs. J Am Soc Nephrol 11: 1122-1131
12. Keown P, Landsberg D, Halloran P et al 1996 A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal allograft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 62: 1744-1752
13. Keown for the Canadian Neoral Renal Transplantation Study Group 2001 Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 72: 1024-1032
14. 2 monitoring of cyclosporine immunosuppression. BioDrugs 15: 279-290
15. Lindholm A, Kahan BD 1993 Influence of cyclosporine pharmacokinetics, trough concentrations and AUC monitoring on outcomes after kidney transplantation. Clin Pharmacol Ther 54: 205-218
16. Mahalati K, Belitsky P et al 1999 Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 68: 55-62
17. Meier-Kriesche HU et al 2000 Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 70: 1098-1100
18. Neumayer HH, Färber L, Haller P, Kohnen R, Maibücher A, Schuster A, Vollmar J, Budde K, Raiser J, Luft FC 1996 Substitution of conventional cyclosporine with a new microemulsion formulation in renal transplant patients: results after 1 year. Nephrol Dial Transplant 11: 165-172
19. Perner for the International Neoral Renal Transplantation Study Group 2002 Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2: 148-156
20. Schroeder TJ, Hariharan S, First MR 1995 Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations. Transplant Proc 27: 837-839
21. Shibata N, Hoshino N, Minouchi T, Yamaji A, Park K, Tomoyoshi T, Abe H, Kodama M 1998 Relationship between area under the concentration versus time curve of cyclosporin A, creatinine clearance, hematocrit value and other clinical factors in Japanese renal transplant patients. Int J Clin Pharmacol Ther 36: 202-209
22. Sindhi R, La Via MF, Paulling E et al 2000 Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine + rapamycin regimen. Transplantation 69: 432-436
23. Waiser J, Slowinski T, Budde K, Neumayer HH et al 2000 Impact of the variability of cyclosporin A trough levels on long-term allograft function. Nephrol Dial Transplant 17: 1310-1317